3-D printed device delivers drugs in human... A research team headed by Jean-Christophe Leroux from ETH Zurüch has created the first-ever 3-D printed mouth guard that could deliver drugs to the wearer and is highly customizable, in terms of drug … more ➔
Shire accepts €52.4bn takeover bid by Ta...Following weeks of negotiations and four rejected bids, British neurology and orphan drug giant Shire has agreed to Takedas latest take-over offer of £46bn (€52,38bn). more ➔
Narasimhan embraces Swiss biotech industryVas Narasimhan, the newly appointed CEO of Swiss pharma giant Novartis, introduced himself to the Swiss biotech industry with a stimulant talk at the Swiss Biotech Day. Apart from that participants of … more ➔
Partnership drives connectivity in injecti...Swiss injection pen developer Haselmeier and Boston-based Common Sensing have partnered to develop smart connected self-injection devices that can monitor drug administration, dosing and efficacy of … more ➔
Go Jelly, goThe UK-based pioneer in marine biotechnologies Jellagen has closed a £3.8m funding round to boost sales of its next-generation jellyfish-based medicine. Lead investor were Newable Private Investing … more ➔
Irish Iterum files for IPO on NasdaqIterum Therapeutics plans to raise up to US$92m in an initial public offering on US technology stock market Nasdaq. The Irish company develops oral and IV antibiotics for urinary tract infections and … more ➔
Near-term capital for NeurimmuneUS biotech company Biogen has exercised the option of a one-off payment to Swiss developer Neurimmune. If Biogen’s Alzheimer’s candidate Aducanumab is approved, the sales-related payments to Neurimmune … more ➔
Diabetes drug reverses PAHA new study shows that a drug approved for the treatment of diabetes reverses pulmonary arterial hypertension (PAH) and prevents right heart failure in rats. Ekaterina Legchenko and colleagues say their … more ➔
Targovax gives pipeline updateNorwegian Targovax ASA has given an update of its immunononcology and pancreatic cancer clinical pipeline at ChinaBio Conference in Suzhou. more ➔
AZs Durvalumab/Tremelimumab combo flops...British drug maker AstraZeneca has failed to expand the reach of its combo of PD-1/CTLA4 checkpoint blockers Durvalumab/Tremelimumab. The approved second-line NSCLC treatment missed to prolong … more ➔
